Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Kim, Wun Jae ^a,b   Kim, Eun Jung ^a,b   Kim, Seon Kyu ^a   Kim, Yong June ^a,b   Ha, Yun Sok ^a   Jeong, Pildu ^a   Kim, Min Ju ^a   Yun, Seok Joong ^a   Lee, Keon M ^b   Moon, Sung Kwon ^c   Lee, Sang Cheol ^a   Cha, Eun Jong ^a   Bae, Suk Chul ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Chungbuk National University   (South Korea)

^c Chungju National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CLASSIFIER; COMPUTER PREDICTION; FEMALE; GENE CLASSIFIER; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; NUCLEOTIDE SEQUENCE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; BLADDER TUMOR; CLUSTER ANALYSIS; COHORT ANALYSIS; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MUSCLE; PATHOLOGY; REPRODUCIBILITY; TUMOR CELL CULTURE; TUMOR GENE;

AGED; CLUSTER ANALYSIS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MUSCLES; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 76749089153     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-3     Document Type: Article

References (39)

1. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, Xu HJ, Reuter VE, Benedict WF. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997, 57:1217-1221.
2. Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, Schmitz-Drager BJ, Murphy WM, Bono AV, Goebell P, et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 2005, 66:64-74. 10.1016/j.urology.2005.08.065, 16399416.
3. Liou LS. Urothelial cancer biomarkers for detection and surveillance. Urology 2006, 67:25-33. discussion 33-24, 10.1016/j.urology.2006.01.034, 16530072.
4. Bubendorf L. High-throughput microarray technologies: from genomics to clinics. Eur Urol 2001, 40:231-238. 10.1159/000049777, 11528203.
5. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006, 354:2463-2472. 10.1056/NEJMra042342, 16760446.
6. Kim WJ, Bae SC. Molecular biomarkers in urothelial bladder cancer. Cancer Sci 2008, 99:646-652. 10.1111/j.1349-7006.2008.00735.x, 18377416.
7. Kim WJ, Quan C. Genetic and epigenetic aspects of bladder cancer. J Cell Biochem 2005, 95:24-33. 10.1002/jcb.20412, 15759278.
8. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 58566, 11553815, 10.1073/pnas.191367098.
9. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8:819-824.
10. Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967, 12490681.
11. Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, Kitahara O, Zembutsu H, Yanagawa R, Hirata K, et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 2001, 61:6474-6479.
12. van 't Veer LJ, Dai H, Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, Kooy K, Marton MJ, Witteveen AT, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
13. Kallioniemi O. Medicine: profile of a tumour. Nature 2004, 428:379-382. 10.1038/428379b, 15042074.
14. American Joint Committee on Cancer Urinary bladder. American Joint Committee on Cancer: Cancer Staging Manual 2002, 335-340. New York, NY, Springer, Greene FL, 6, American Joint Committee on Cancer.
15. Reuter VE, Melamed MR. The lower urinary tract. Diagnostic Surgical Pathology 1989, 1355-1392. New York, NY, Raven Press, Sternberg SS.
16. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008, 54:303-314. 10.1016/j.eururo.2008.04.051, 18468779.
17. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS, Schellhammer PF. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007, 178:2314-2330. 10.1016/j.juro.2007.09.003, 17993339.
18. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA. The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. Eur Urol 2009,
19. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193. 10.1093/bioinformatics/19.2.185, 12538238.
20. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868. 24541, 9843981, 10.1073/pnas.95.25.14863.
21. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007, 356:11-20. 10.1056/NEJMoa060096, 17202451.
22. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004, 350:1828-1837. 10.1056/NEJMoa032520, 15115829.
23. Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, Rzyman W, Gulida G, Raz D, Jablons D, Provencio M, et al. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 2008, 14:4794-4799. 10.1158/1078-0432.CCR-08-0576, 18676750.
24. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
25. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006, 24:778-789. 10.1200/JCO.2005.03.2375, 16432078.
26. Dyrskjot L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S, Knowles M, Malmstrom PU, de la Torre M, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007, 13:3545-3551. 10.1158/1078-0432.CCR-06-2940, 17575217.
27. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H, Orntoft TF. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003, 33:90-96. 10.1038/ng1061, 12469123.
28. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007, 99:147-157. 10.1093/jnci/djk018, 17227998.
29. Chuaqui RF, Bonner RF, Best CJ, Gillespie JW, Flaig MJ, Hewitt SM, Phillips JL, Krizman DB, Tangrea MA, Ahram M, et al. Post-analysis follow-up and validation of microarray experiments. Nat Genet 2002, 32(Suppl):509-514. 10.1038/ng1034, 12454646.
30. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005, 365:488-492. 10.1016/S0140-6736(05)17866-0, 15705458.
31. Yao R, Davidson DD, Lopez-Beltran A, MacLennan GT, Montironi R, Cheng L. The S100 proteins for screening and prognostic grading of bladder cancer. Histol Histopathol 2007, 22:1025-1032.
32. Bobarykina AY, Minchenko DO, Opentanova IL, Moenner M, Caro J, Esumi H, Minchenko OH. Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers. Acta Biochim Pol 2006, 53:789-799.
33. Minchenko OH, Ochiai A, Opentanova IL, Ogura T, Minchenko DO, Caro J, Komisarenko SV, Esumi H. Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors. Biochimie 2005, 87:1005-1010. 10.1016/j.biochi.2005.04.007, 15925437.
34. Loboda A, Jazwa A, Grochot-Przeczek A, Rutkowski AJ, Cisowski J, Agarwal A, Jozkowicz A, Dulak J. Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2008, 10:1767-1812. 10.1089/ars.2008.2043, 18576916.
35. Huang SK, Chiu AW, Pu YS, Huang YK, Chung CJ, Tsai HJ, Yang MH, Chen CJ, Hsueh YM. Arsenic methylation capability, heme oxygenase-1 and NADPH quinone oxidoreductase-1 genetic polymorphisms and the stage and grade of urothelial carcinomas. Urol Int 2008, 80:405-412. 10.1159/000132699, 18587252.
36. Christopher SA, Diegelman P, Porter CW, Kruger WD. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res 2002, 62:6639-6644.
37. Lee JR, Shin H, Ko J, Choi J, Lee H, Kim E. Characterization of the movement of the kinesin motor KIF1A in living cultured neurons. J Biol Chem 2003, 278:2624-2629. 10.1074/jbc.M211152200, 12435738.
38. Tuckwell D. Evolution of von Willebrand factor A (VWA) domains. Biochem Soc Trans 1999, 27:835-840.
39. Sylvester RJ, Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-465. discussion 475-467, 10.1016/j.eururo.2005.12.031, 16442208.